[{"id":"574e6b32-3215-4f0b-89b9-a7be4c7b974c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02400385","created_at":"2021-01-18T11:27:10.795Z","updated_at":"2024-07-02T16:37:26.059Z","phase":"Phase 2","brief_title":"A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma","source_id_and_acronym":"NCT02400385","lead_sponsor":"California Pacific Medical Center Research Institute","biomarkers":" BRAF • KIT","pipe":" | ","alterations":" KIT mutation • KIT fusion • KIT translocation","tags":["BRAF • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT fusion • KIT translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sunitinib"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-02-01"}]